Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Dächsel JC[au]:

VPS35 mutations in Parkinson disease. Vilariño-Güell C et al. Am J Hum Genet. (2011)

Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells. Thirstrup K et al. Sci Rep. (2017)

LRRK2 and Parkinson disease. Dächsel JC et al. Arch Neurol. (2010)

Search results

Items: 28

1.

Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.

Thirstrup K, Dächsel JC, Oppermann FS, Williamson DS, Smith GP, Fog K, Christensen KV.

Sci Rep. 2017 Aug 31;7(1):10300. doi: 10.1038/s41598-017-10501-z.

2.

The Rho guanine nucleotide exchange factor Syx regulates the balance of dia and ROCK activities to promote polarized-cancer-cell migration.

Dachsel JC, Ngok SP, Lewis-Tuffin LJ, Kourtidis A, Geyer R, Johnston L, Feathers R, Anastasiadis PZ.

Mol Cell Biol. 2013 Dec;33(24):4909-18. doi: 10.1128/MCB.00565-13. Epub 2013 Oct 14.

3.

LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors.

Hinkle KM, Yue M, Behrouz B, Dächsel JC, Lincoln SJ, Bowles EE, Beevers JE, Dugger B, Winner B, Prots I, Kent CB, Nishioka K, Lin WL, Dickson DW, Janus CJ, Farrer MJ, Melrose HL.

Mol Neurodegener. 2012 May 30;7:25. doi: 10.1186/1750-1326-7-25.

4.

Translation initiator EIF4G1 mutations in familial Parkinson disease.

Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, Lincoln SJ, Leprêtre F, Hulihan MM, Kachergus J, Milnerwood AJ, Tapia L, Song MS, Le Rhun E, Mutez E, Larvor L, Duflot A, Vanbesien-Mailliot C, Kreisler A, Ross OA, Nishioka K, Soto-Ortolaza AI, Cobb SA, Melrose HL, Behrouz B, Keeling BH, Bacon JA, Hentati E, Williams L, Yanagiya A, Sonenberg N, Lockhart PJ, Zubair AC, Uitti RJ, Aasly JO, Krygowska-Wajs A, Opala G, Wszolek ZK, Frigerio R, Maraganore DM, Gosal D, Lynch T, Hutchinson M, Bentivoglio AR, Valente EM, Nichols WC, Pankratz N, Foroud T, Gibson RA, Hentati F, Dickson DW, Destée A, Farrer MJ.

Am J Hum Genet. 2011 Sep 9;89(3):398-406. doi: 10.1016/j.ajhg.2011.08.009.

5.

VPS35 mutations in Parkinson disease.

Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Soto-Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, Behrouz B, Melrose HL, Hentati E, Puschmann A, Evans DM, Conibear E, Wasserman WW, Aasly JO, Burkhard PR, Djaldetti R, Ghika J, Hentati F, Krygowska-Wajs A, Lynch T, Melamed E, Rajput A, Rajput AH, Solida A, Wu RM, Uitti RJ, Wszolek ZK, Vingerhoets F, Farrer MJ.

Am J Hum Genet. 2011 Jul 15;89(1):162-7. doi: 10.1016/j.ajhg.2011.06.001. Erratum in: Am J Hum Genet. 2011 Aug 12;89(2):347.

6.

Death-associated protein kinase 1 variation and Parkinson's disease.

Dachsel JC, Wider C, Vilariño-Güell C, Aasly JO, Rajput A, Rajput AH, Lynch T, Craig D, Krygowska-Wajs A, Jasinska-Myga B, Opala G, Barcikowska M, Czyzewski K, Wu RM, Heckman MG, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA.

Eur J Neurol. 2011 Aug;18(8):1090-3. doi: 10.1111/j.1468-1331.2010.03255.x. Epub 2010 Nov 30.

PMID:
21749573
7.

P25α / TPPP expression increases plasma membrane presentation of the dopamine transporter and enhances cellular sensitivity to dopamine toxicity.

Fjorback AW, Sundbye S, Dächsel JC, Sinning S, Wiborg O, Jensen PH.

FEBS J. 2011 Feb;278(3):493-505. doi: 10.1111/j.1742-4658.2010.07970.x. Epub 2010 Dec 23.

8.

A comparative study of Lrrk2 function in primary neuronal cultures.

Dächsel JC, Behrouz B, Yue M, Beevers JE, Melrose HL, Farrer MJ.

Parkinsonism Relat Disord. 2010 Dec;16(10):650-5. doi: 10.1016/j.parkreldis.2010.08.018. Epub 2010 Sep 17.

9.

Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.

Aasly JO, Vilariño-Güell C, Dachsel JC, Webber PJ, West AB, Haugarvoll K, Johansen KK, Toft M, Nutt JG, Payami H, Kachergus JM, Lincoln SJ, Felic A, Wider C, Soto-Ortolaza AI, Cobb SA, White LR, Ross OA, Farrer MJ.

Mov Disord. 2010 Oct 15;25(13):2156-63. doi: 10.1002/mds.23265.

10.

Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.

Melrose HL, Dächsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM, Kent CB, Korvatska E, Taylor JP, Witten L, Liang YQ, Beevers JE, Boules M, Dugger BN, Serna VA, Gaukhman A, Yu X, Castanedes-Casey M, Braithwaite AT, Ogholikhan S, Yu N, Bass D, Tyndall G, Schellenberg GD, Dickson DW, Janus C, Farrer MJ.

Neurobiol Dis. 2010 Dec;40(3):503-17. doi: 10.1016/j.nbd.2010.07.010. Epub 2010 Jul 24.

11.

LRRK2 and Parkinson disease.

Dächsel JC, Farrer MJ.

Arch Neurol. 2010 May;67(5):542-7. doi: 10.1001/archneurol.2010.79. Review.

PMID:
20457952
12.

Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease.

Dachsel JC, Nishioka K, Vilariño-Güell C, Lincoln SJ, Soto-Ortolaza AI, Kachergus J, Hinkle KM, Heckman MG, Jasinska-Myga B, Taylor JP, Dickson DW, Gibson RA, Hentati F, Ross OA, Farrer MJ.

Mech Ageing Dev. 2010 Mar;131(3):210-4. doi: 10.1016/j.mad.2010.01.009. Epub 2010 Feb 6.

13.

Elucidating the genetics and pathology of Perry syndrome.

Wider C, Dachsel JC, Farrer MJ, Dickson DW, Tsuboi Y, Wszolek ZK.

J Neurol Sci. 2010 Feb 15;289(1-2):149-54. doi: 10.1016/j.jns.2009.08.044. Epub 2009 Sep 4.

14.

LINGO1 rs9652490 is associated with essential tremor and Parkinson disease.

Vilariño-Güell C, Ross OA, Wider C, Jasinska-Myga B, Cobb SA, Soto-Ortolaza AI, Kachergus JM, Keeling BH, Dachsel JC, Melrose HL, Behrouz B, Wszolek ZK, Uitti RJ, Aasly JO, Rajput A, Farrer MJ.

Parkinsonism Relat Disord. 2010 Feb;16(2):109-11. doi: 10.1016/j.parkreldis.2009.08.006. Epub 2009 Aug 31.

15.

GCH1 expression in human cerebellum from healthy individuals is not gender dependent.

Wider C, Lincoln S, Dachsel JC, Kapatos G, Heckman MG, Diehl NN, Papapetropoulos S, Mash D, Rajput A, Rajput AH, Dickson DW, Wszolek ZK, Farrer MJ.

Neurosci Lett. 2009 Oct 2;462(1):73-5. doi: 10.1016/j.neulet.2009.06.082. Epub 2009 Jun 30.

16.

Characterization of DCTN1 genetic variability in neurodegeneration.

Vilariño-Güell C, Wider C, Soto-Ortolaza AI, Cobb SA, Kachergus JM, Keeling BH, Dachsel JC, Hulihan MM, Dickson DW, Wszolek ZK, Uitti RJ, Graff-Radford NR, Boeve BF, Josephs KA, Miller B, Boylan KB, Gwinn K, Adler CH, Aasly JO, Hentati F, Destée A, Krygowska-Wajs A, Chartier-Harlin MC, Ross OA, Rademakers R, Farrer MJ.

Neurology. 2009 Jun 9;72(23):2024-8. doi: 10.1212/WNL.0b013e3181a92c4c.

17.

DCTN1 mutations in Perry syndrome.

Farrer MJ, Hulihan MM, Kachergus JM, Dächsel JC, Stoessl AJ, Grantier LL, Calne S, Calne DB, Lechevalier B, Chapon F, Tsuboi Y, Yamada T, Gutmann L, Elibol B, Bhatia KP, Wider C, Vilariño-Güell C, Ross OA, Brown LA, Castanedes-Casey M, Dickson DW, Wszolek ZK.

Nat Genet. 2009 Feb;41(2):163-5. doi: 10.1038/ng.293. Epub 2009 Jan 11.

18.

FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression.

Wider C, Dachsel JC, Soto AI, Heckman MG, Diehl NN, Yue M, Lincoln S, Aasly JO, Haugarvoll K, Trojanowski JQ, Papapetropoulos S, Mash D, Rajput A, Rajput AH, Gibson JM, Lynch T, Dickson DW, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA.

Mov Disord. 2009 Feb 15;24(3):455-9. doi: 10.1002/mds.22442.

19.

Proteasomal inhibition reduces parkin mRNA in PC12 and SH-SY5Y cells.

Koch A, Lehmann-Horn K, Dächsel JC, Gasser T, Kahle PJ, Lücking CB.

Parkinsonism Relat Disord. 2009 Mar;15(3):220-5. doi: 10.1016/j.parkreldis.2008.05.005. Epub 2008 Jun 30.

PMID:
18586549
20.

A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease.

Melrose HL, Kent CB, Taylor JP, Dachsel JC, Hinkle KM, Lincoln SJ, Mok SS, Culvenor JG, Masters CL, Tyndall GM, Bass DI, Ahmed Z, Andorfer CA, Ross OA, Wszolek ZK, Delldonne A, Dickson DW, Farrer MJ.

Neuroscience. 2007 Jul 29;147(4):1047-58. Epub 2007 Jul 3.

PMID:
17611037
21.

Identification of potential protein interactors of Lrrk2.

Dächsel JC, Taylor JP, Mok SS, Ross OA, Hinkle KM, Bailey RM, Hines JH, Szutu J, Madden B, Petrucelli L, Farrer MJ.

Parkinsonism Relat Disord. 2007 Oct;13(7):382-5. Epub 2007 Apr 2.

22.

Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia.

Farrer MJ, Stone JT, Lin CH, Dächsel JC, Hulihan MM, Haugarvoll K, Ross OA, Wu RM.

Parkinsonism Relat Disord. 2007 Mar;13(2):89-92. Epub 2007 Jan 10.

PMID:
17222580
23.

Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions.

Dächsel JC, Ross OA, Mata IF, Kachergus J, Toft M, Cannon A, Baker M, Adamson J, Hutton M, Dickson DW, Farrer MJ.

Acta Neuropathol. 2007 May;113(5):601-6. Epub 2006 Dec 7.

PMID:
17151837
24.

Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2.

Dächsel JC, Mata IF, Ross OA, Taylor JP, Lincoln SJ, Hinkle KM, Huerta C, Ribacoba R, Blazquez M, Alvarez V, Farrer MJ.

Neurosci Lett. 2006 Dec 20;410(2):80-4.

PMID:
17095157
25.

The ups and downs of alpha-synuclein mRNA expression.

Dächsel JC, Lincoln SJ, Gonzalez J, Ross OA, Dickson DW, Farrer MJ.

Mov Disord. 2007 Jan 15;22(2):293-5. Review. No abstract available.

PMID:
17094104
26.

Parkinsonism, Lrrk2 G2019S, and tau neuropathology.

Rajput A, Dickson DW, Robinson CA, Ross OA, Dächsel JC, Lincoln SJ, Cobb SA, Rajput ML, Farrer MJ.

Neurology. 2006 Oct 24;67(8):1506-8.

PMID:
17060589
27.

Pathogenic Lrrk2 substitutions and Amyotrophic lateral sclerosis.

Whittle AJ, Ross OA, Naini A, Gordon P, Mistumoto H, Dächsel JC, Stone JT, Wszolek ZK, Farrer MJ, Przedborski S.

J Neural Transm (Vienna). 2007 Mar;114(3):327-9. Epub 2006 Jul 25.

PMID:
16865326
28.

Parkin interacts with the proteasome subunit alpha4.

Dächsel JC, Lücking CB, Deeg S, Schultz E, Lalowski M, Casademunt E, Corti O, Hampe C, Patenge N, Vaupel K, Yamamoto A, Dichgans M, Brice A, Wanker EE, Kahle PJ, Gasser T.

FEBS Lett. 2005 Jul 18;579(18):3913-9.

Supplemental Content

Loading ...
Support Center